Sanofi has announced that the CHMP of the European Medicines Agency has recommended extending the indications of Dupixent (dupilumab) in the European Union to the treatment of severe atopic dermatitis in young children aged six months and over.

This opinion is based on data from the Phase III trial, which showed that Dupixent improved skin healing, reduced overall disease severity and improved health-related quality of life, in children aged between six months and five years.

In Europe, around 80,000 children in this age group suffering from this disease are candidates for systemic treatment. If approved, Dupixent will be the first and only targeted drug available in the EU for the treatment of these young children.

Copyright (c) 2023 CercleFinance.com. All rights reserved.